CytoDyn

289 articles with CytoDyn

• CytoDyn to Hold Webcast and Live Q/A on October 26

  10/21/2021

  CytoDyn Inc. announced Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, Nitya Ray, Ph.D., Chief Operating Officer and Chief Technology Officer and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations of CytoDyn will host an investment community webcast on Tuesday, October 26, 2021.

• CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting

  10/18/2021

  CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting

• Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid

  10/14/2021

  CytoDyn Inc. today announced that the Delaware Court of Chancery found that CytoDyn’s Board of Directors properly rejected a nomination notice presented by an activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group” or the “Activist Group”).

• CytoDyn to Present at Emerging Growth Conference on October 13 Followed by Live Q/A

  10/7/2021

  CytoDyn Inc. announced Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, Nitya Ray, Ph.D., Chief Operating Officer and Chief Technology Officer and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference.

• CytoDyn Names Chris Recknor, M.D. Senior Executive VP of Clinical Operations to Initiate Two New Clinical Trials for Stroke and Alzheimer’s

  10/7/2021

  New hires in Bioanalytical Sciences, Biostatistics, Clinical Regulatory, and Clinical Project Management will join the team of Drs. Srinivasan, Recknor, Ray, and Kelly to lead all clinical trials with new CROs

• CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB)

  10/7/2021

  CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a study for treating triple-negative breast cancer with leronlimab in a humanized TNBC xenograft model.

• CytoDyn Announces Legal Actions Against its Former CRO, Amarex Clinical Research

  10/7/2021

  CytoDyn Inc. announced today the filing of a complaint for declaratory and injunctive relief and motion for a preliminary injunction against NSF International, Inc. and its subsidiary Amarex Clinical Research (“Amarex”), the Company’s former Contract Research Organization (“CRO”).

• CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A

  9/27/2021

  CytoDyn Inc. announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference.

• Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab

  9/24/2021

  A group of long-time stockholders today announced its comprehensive strategic plan to obtain cancer therapy approval for Leronlimab.

• CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)

  9/22/2021

  CytoDyn Inc. today announced that Brazil’s regulatory authority, ANVISA (Agência Nacional de Vigilância Sanitária), has approved the start of an additional Phase 3 CD16 clinical trial of leronlimab.

• CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021

  9/21/2021

  CytoDyn Inc. today announced that Dr. Scott Kelly, CytoDyn’s Chairman of the Board, Chief Medical Officer and Head of Business Development, will be presenting at the World Antiviral Congress 2021.

• Group of CytoDyn Stockholders Announces Federal Court Dismisses Litigation Brought by Company

  9/20/2021

  A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. today announced that Judge Maryellen Noreika has approved a joint stipulation to dismiss CYDY’s lawsuit in the United States District Court for the District of Delaware.

• CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A

  9/13/2021

  CytoDyn Inc. announced Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference.

• 

  Clinical Catch-Up: September 6-10

  9/13/2021

  It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.

• CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms

  9/10/2021

  CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the treatment of the first patient in its pivotal Phase 3 COVID-19 trial in Brazil for patients with severe symptoms.

• CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials

  9/2/2021

  CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Chief Operating Officer and Head of Clinical Development, will host an investment community webcast on Wednesday, September 8, 2021.

• CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival

  8/25/2021

  CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced an update to previously reported preliminary results from its Phase 1b/2 trials and compassionate use with leronlimab to treat a total of 30 metastatic triple-negative breast cancer patients.

• CytoDyn Receives FDA Guidance for its HIV BLA Dose Justification Report

  8/13/2021

  CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that it received comments from the U.S. Food and Drug Administration on the Company’s recently submitted dose justification report, an important component to the Company’s resubmission of its Biologics License Application for HIV.

• 

  CytoDyn Fights Back Against Activist Group

  8/5/2021

  CytoDyn files a lawsuit against the activist group led by Rosenbaum and Patterson, alleging that they are "waging an illegal proxy contest to take over control of the Company's Board of Directors."

• CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

  8/3/2021

  CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that Brazil’s regulatory authority ANVISA has approved the previously submitted clinical trial protocol to commence patient enrollment in its CD17 trial for severe COVID-19 patients.